BioNTech is trading 14.29% up at $106.00 with no clear company-specific catalyst identified for August 19, 2026.
- Its latest major event was the August 4 second-quarter report, which included weaker revenue and reduced 2026 guidance rather than fresh overnight news.
- The broader market is mixed, with Nasdaq futures slightly lower, so macro sentiment does not clearly explain the sharp move.
- Recheck for delayed filings, clinical updates, or analyst actions.